Business
Q1 trading update and outlook for 2026
CelLBxHealth plc reported its Q1 2026 trading update, highlighting significant cost-saving measures that have reduced annual cash operating costs by over £6.6 million, with a further £0.1 million expected in Q2 2026, bringing headcount down to 39 FTEs. The company ended Q1 with £4.3 million in cash. Looking ahead, CelLBxHealth is confident in achieving FY 2026 revenues of at least £2.1 million, a 50% increase from FY 2025, and is in advanced discussions with a major US healthcare provider and a top ten global pharmaceutical company regarding its Parsortix® platform. Disclaimer*
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n\n \nCelLBxHealth plc\n (\"CelLBxHealth\" or \"the Company\")\n \nQ1 trading update and outlook for 2026\n \nGuildford, UK and Plymouth Meeting, U.S. - 11 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, provides a trading update for Q1 2026 and outlook for FY 2026 (year ending 31 December 2026).\n \nTrading in first quarter of the year, reflected the Company's initial focus on the necessary organisational restructuring required under the revised business strategy. Management have concentrated efforts on securing significant cost-saving measures, whilst ensuring the business is right-sized to deliver on sensible commercial milestones and to execute on key leads within the sales pipeline. Following last year's 60% reduction in headcount the business has been further reduced from 44 full-time employees (FTEs) to 39 FTEs in the first quarter. These actions, combined with additional forecast cost saving efforts, have resulted in reducing annual cash operating costs in 2026 by more than £6.6 million. Further identified costs to be rationalised in Q2 2026 are expected to deliver savings of an additional £0.1 million. Cash at 31 March 2026 was £4.3 million, in-line with expectations and reflecting one-off costs associated with the restructuring of the business.\n \nOutlook for 2026\n \nWhilst making the much-needed cost reductions, as detailed above, there is also an acute focus on driving commercial progress and revenue growth; accordingly the Company has appointed a new head of sales in the US. The Board remains confident in delivering significant growth in 2026 and the qualified sales pipeline continues to build. It remains early in the Company's turnaround, but based on contracted revenues and sales opportunities expected to...